Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of “Buy” by Analysts
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned a consensus rating of “Buy” from the seventeen analysts that are presently covering the firm, Marketbeat reports. Seventeen analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is […]
More Stories
Musk Launches PAC to Back Candidates Focused on Secure Borders, Free Speech, Sensible Spending
By Tom Ozimek Business mogul Elon Musk has launched a new political action committee (PAC), called America PAC, to endorse...
Bank of South Carolina Co. (BKSC) To Go Ex-Dividend on October 8th
Bank of South Carolina Co. (NASDAQ:BKSC – Get Free Report) announced a quarterly dividend on Thursday, September 26th, NASDAQ reports....
BNY Mellon High Yield Strategies Fund (NYSE:DHF) to Issue Monthly Dividend of $0.02
BNY Mellon High Yield Strategies Fund (NYSE:DHF – Get Free Report) announced a monthly dividend on Tuesday, September 24th, Wall...
Sabine Royalty Trust (NYSE:SBR) to Issue Monthly Dividend of $0.44
Sabine Royalty Trust (NYSE:SBR – Get Free Report) announced a monthly dividend on Friday, October 4th, Zacks reports. Shareholders of...
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP) To Go Ex-Dividend on December 13th
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (NYSE:OPP – Get Free Report) declared a monthly dividend on Friday, October 4th, Wall Street...
Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $10,313.31 in Stock
Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) Director William Richard White sold 201 shares of the business’s stock in...